Clinical Trial

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2022-04-25; most recent amendment 2026-01-12.
Status change: Recruiting → Active, Not Recruiting 2025-01-23
Status change: Not Yet Recruiting → Recruiting 2022-06-17
Trial Details
NCT Number NCT05353257
Lead Sponsor Shanghai Henlius Biotech
Conditions Limited-Stage Small Cell Lung Cancer
Enrollment 511 participants
Start Date 2022-05-17
Primary Completion 2026-06-30 (estimated)
Study Completion 2028-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-13